TAILORX trial results Monday, September 28

Hi:

Today, I was still able to access the text of the first two abstracts only. The others may be embargoed (held until a certain date):

Abstract number: 1943

http://www.europeancancercongress.org/Scientific-P...

Abstract number: 1963

http://www.europeancancercongress.org/Scientific-P...

Please note that abstracts can be preliminary. More data and information will be presented at the conference, and fully peer-reviewed publications should follow in due course.

Voraciousreader indicated in another thread that "peer review data has been submitted to the necessary journals and there is an embargo until that date. Additional info and discussion will also occur at the San Antonio Breast Cancer Symposium during the first week in December."

BarredOwl

I assume this is an update to the trial, since according to the trial link on clinicaltrials.gov,
completion date is slated for Dec 2017.

Estimated Enrollment: 11248
Study Start Date: April 2006
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

I agree. I assume they will continue to follow patients for decades and report results every few years.
Given the phenomenon that ER+ cancer cells may stay dormant for a protracted period of time, results in another ten years would be more powerful, imo.
By then of course, we will hopefully have elucidated more on the reasons for recurrences (mechanisms of the angiogenic switch, immunosurveillance, microenvironmental cues, etc).

SABCS just posted abstracts to their website.
Here's a link to a TAILORx poster session called: "Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry".

Poster Session 2
Category: Prognostic and Predictive Factors: Prognostic Factors - Clinical Testing and Validation

P2-08-01
Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D, Geyer C, Dees E, Perez E, Olson J, Zujweski J, Keane M, Moreno HG, Reddi R, Goggins T, Mayer I, Brufsky A, Toppmeyer D, Kaklamani V, Atkins J, Berenberg J, Sledge G.
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Dana Farber Cancer Institute, Boston, MA; Sunnybrook Research Institute, Toronto, ON, Canada; Loyola University Medical Center, Maywood, IL; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Jacksonville, FL; Duke University Medical Center, Durham, NC; National Cancer Institute, Bethesda, MD; University College Hospital, Galway, Ireland; Oncosalud SAC, Lima, Peru; Via Christi Regional Medical Center, Wichita, KS; Fox Valley Hematology and Oncology, Appleton, WI; Vanderbilt University, Nashville, TN; University of Pittsburgh, Pittsburgh, PA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Northwestern University, Chicago, IL; Southeast Clinical Oncology Research Consortium, Goldsboro, NC; University of Hawaii Cancer Center, Honolulu, HI; Stanford University, Stanford, CA.

Hi:

Further to my post above with links to abstracts 1943 and 1963, the text of abstract 1937 is now available:

Abstract 1937: http://www.europeancancercongress.org/Scientific-P...

Please note that abstracts can be preliminary.

BarredOwl